PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Formulary Search

Search

Reset

BNF Chapter

BNF Paragraph

Please select a BNF Chapter.

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A to Z of Drugs : R

Records returned : 78 (on 21 Nov 2024 at 16:59:42).

Drug
Indication
Status
Trust Alignment
Links
Restrictions/Comments
01.03.05
Rabeprazole sodium
Acid suppression (Adults)
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
2nd line in adults without swallowing difficulties. (Suitable for patients that cannot have animal-derived products / capsules.)
Rabies
No Information Returned
Rabies immunoglobulin
No Information Returned
01.04.03
Racecadotril
Diarrhoea
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD1
06.04.01
08.03.04
Raloxifene hydrochloride
Breast cancer - chemoprevention
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
U
NICE
05.03.01
Raltegravir
POST-exposure prophylaxis of HIV-1 infection
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
NHSE
Important
For post-exposure prophylaxis (e.g. needlestick injuries), follow your organisation's protocols for referral and access. Use as recommended by BHIVA/BASHH guidelines.
Raltegravir and Emtricitabine/Tenofovir disoproxil
No Information Returned
Raltitrexed
No Information Returned
02.05.05
Ramipril
Hypertension
Green
Formulations :
  • Capsules
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
Preferred
Use an ARB where possible. If an ACEi is required (patient with heart failure or post MI), ramipril is the preferred option.
02.05.05
Ramipril
Heart failure
Green
Formulations :
  • Capsules
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Preferred
Ramipril with calcium channel blocker
No Information Returned
Ramucirumab
No Information Returned
11.08.02
Ranibizumab
Retinal Vein Occlusion
Red
Formulations :
  • Intravitreal injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
ICB
BlueTeq
NICE
11.08.02
Ranibizumab
Diabetic macular oedema
Red
Formulations :
  • Intravitreal injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
ICB
BlueTeq
NICE
11.08.02
Ranibizumab
Wet age-related macular degeneration
Red
Formulations :
  • Intravitreal injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
ICB
BlueTeq
NICE
11.08.02
Ranibizumab
Myopic choroidal neovascularisation
Red
Formulations :
  • Intravitreal injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
ICB
BlueTeq
NICE
01.03.01
Ranitidine
Acid suppression (Adults)
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD1
U
Ranitidine bismuth citrate
No Information Returned
Ranitidine hydrochloride
No Information Returned
02.06.03
Ranolazine
Angina
Amber
Formulations :
  • Modified release tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Restricted to cardiology
04.09.01
Rasagiline
Parkinson's disease (neuroprotective therapy)
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD1
04.09.01
Rasagiline mesilate
Parkinson's disease
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
10.01.04
Rasburicase
Hyperuricaemia and Gout
Red
Formulations :
  • Intravenous infusion
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NHSE
Ravulizumab
No Information Returned
Razoxane
No Information Returned
Ready to serve 1 - 1.3 kcal/ml m/sk lower energy (0913011)
No Information Returned
Reboxetine
No Information Returned
Regorafenib
No Information Returned
Remifentanil hydrochloride
No Information Returned
Repaglinide
No Information Returned
Reslizumab
No Information Returned
Resorcinol
No Information Returned
Retapamulin
No Information Returned
Reteplase
No Information Returned
Retigabine
No Information Returned
Reviparin sodium
No Information Returned
05.03.03
05.03.05
Ribavirin
Hepatitis C
Red
Formulations :
  • Capsules
  • Injection
  • Oral solution
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NHSE
Ribociclib
No Information Returned
Riboflavin
No Information Returned
05.01.09
Rifabutin
Bacterial infection
Red
Formulations :
  • Capsules
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
Restricted Use - requires microbiology or respiratory approval
05.01.07
05.01.09
Rifampicin
Tuberculosis
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
Liaise with Chest Physician. Patients with multi-drug resistant TB should be treated by a specialist centre.
05.01.07
05.01.09
Rifampicin
Surgical
Red
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
Restricted use of injection with bone pate by ENT to reduce infection of autologous bone pate in mastoid obliteration surgery.
Rifampicin combined preparations
No Information Returned
Rifaximin
No Information Returned
Rilpivirine
No Information Returned
04.09.03
Riluzole
Motor neurone disease
Amber
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
NICE
04.07.04
Rimegepant
Migraine (acute)
Green
Formulations :
  • Oral lyophilisates
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
NICE
04.07.04
Rimegepant
Migraine (prevention)
Red
Formulations :
  • Oral lyophilisates
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
ICB
BlueTeq
NICE
Important
For episodic migraine only
Rimexolone
No Information Returned
Rimonabant
No Information Returned
Ringers
No Information Returned
Riociguat
No Information Returned
01.05.03
10.01.03
13.05.02
13.05.03
Risankizumab
Inflammatory bowel disease
Red
Formulations :
  • Subcutaneous injection (sc)
  • Intravenous infusion
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
ICB
BlueTeq
NICE
Important
Adults only
01.05.03
10.01.03
13.05.02
13.05.03
Risankizumab
Psoriasis
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
ICB
BlueTeq
NICE
01.05.03
10.01.03
13.05.02
13.05.03
Risankizumab
Psoriatic arthritis
Red
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
ICB
BlueTeq
NICE
Risedronate sodium
No Information Returned
Risperidone
No Information Returned
Ritodrine hydrochloride
No Information Returned
05.03.01
05.03.03
Ritonavir
Hepatitis C
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
SA
NHSE
Important
Requires approval from HCV national team for use
05.03.01
05.03.03
Ritonavir
HIV infection
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
NHSE
Important
Restricted Antimicrobial - requires GUM Specialist approval
08.02.03
10.01.03
Rituximab
Systemic Lupus Erythematosus
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NHSE
Important
Specialist centres only
08.02.03
10.01.03
Rituximab
Chronic inflammatory demyelinating polyneuropathy
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NHSE
Important
Specialist centres only
08.02.03
10.01.03
Rituximab
Graft versus Host Disease (GVHD)
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NHSE
Important
Specialist centres only
08.02.03
10.01.03
Rituximab
ANCA-positive vasculitis
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NHSE
Important
Specialist centres only
08.02.03
10.01.03
Rituximab
Connective tissue disease
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NHSE
Important
Specialist centres only
08.02.03
10.01.03
Rituximab
Immunoglobulin G4 related disease
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NHSE
Important
Specialist centres only
08.02.03
10.01.03
Rituximab
Sjogren's syndrome
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NHSE
Important
Specialist centres only
08.02.03
10.01.03
Rituximab
Myositis
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NHSE
Important
Specialist centres only
08.02.03
10.01.03
Rituximab
Refractory vasculitis
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NHSE
08.02.03
10.01.03
Rituximab
Any paediatric use
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Specialist centres only
08.02.03
10.01.03
Rituximab
Rheumatoid arthritis
Red
Formulations :
  • Intravenous infusion
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
ICB
BlueTeq
NICE
Important
Severe disease only
02.08.02
Rivaroxaban
Prevention of atherothrombotic events - coronary or peripheral artery disease
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
NICE
02.08.02
Rivaroxaban
Atrial fibrillation
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
02.08.02
Rivaroxaban
Deep Vein Thrombosis (DVT) / Pulmonary Embolism (PE)
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
NICE
Important
Specialist initiation and at least one month supply before transfer to primary care
02.08.02
Rivaroxaban
Prevention of atherothrombotic events - Acute Coronary Syndrome
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
NICE
Important
Specialist initiation and at least one month supply before transfer to primary care
02.08.02
Rivaroxaban
VTE prevention post hip/knee replacement
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
04.11.00
Rivastigmine
Dementia
N/A
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
04.11.00
Rivastigmine
Multiple sclerosis
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD1
04.07.04
Rizatriptan
Migraine (acute)
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Prescribe generically
04.07.04
Rizatriptan
Migraine (acute)
Green (see narrative)
Formulations :
  • Oro-dispersible
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
Prescribe generically
Prescribe as generic orodispersible tablets (NOT oral lyophilisates). For use in patients with swallowing difficulties, nausea or vomitting.
04.07.04
Rizatriptan
Migraine (acute)
Non Formulary
Formulations :
  • Oral lyophilisates
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD1
Important
Prescribe generically
Prescribe as orodispersible tablets
Rocuronium bromide
No Information Returned
Rofecoxib
No Information Returned
Roflumilast
No Information Returned
Rolapitant
No Information Returned
09.01.04
Romiplostim
Immune thrombocytopenia
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
09.01.04
Romiplostim
Immune thrombocytopenia
See Below
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Romosozumab
No Information Returned
Ropeginterferon alfa
No Information Returned
04.09.01
Ropinirole hydrochloride
Parkinson's disease
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
NICE
04.09.01
Ropinirole hydrochloride
Parkinson's disease
Blue
Formulations :
  • Modified release tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
NICE
04.09.01
Ropinirole hydrochloride
Parkinson's disease (neuroprotective therapy)
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD1
Ropivacaine hydrochloride
No Information Returned
Rose bengal
No Information Returned
Rosiglitazone
No Information Returned
02.12.00
Rosuvastatin calcium
Lipid modification
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Rotavirus
No Information Returned
04.09.01
Rotigotine
Restless Leg Syndrome
Green
Formulations :
  • Patches
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Preferred
Patients with severe symptoms, who are obese, co-morbid depression, increased risk of falls or cognitive impairment. Consider use of patch if significant daytime symptoms as it has a long duration of action.
04.09.01
Rotigotine
Parkinson's disease
Blue
Formulations :
  • Patches
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
NICE
Important
Consider patches if levodopa and / or oral dopamine are not effective in treating nocturnal akinesia
Roxadustat
No Information Returned
RtS 1.4 - 2 kcal/ml dessert style (milk based) (0913011)
No Information Returned
RtS 1.5 - 1.6 kcal/ml milkshake higher protein (0913011)
No Information Returned
RtS 1.5 - 1.6 kcal/ml milkshake with fibre (0913011)
No Information Returned
Rubella
No Information Returned
04.08.01
Rufinamide
Epilepsy
Amber
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
SASH - restricted to paediatrics only. RSCH - only initiate on recommendation from a tertiary referral centre.
04.08.01
Rufinamide
Epilepsy
Amber
Formulations :
  • Oral suspension
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
RSCH - only initiate on recommendation from a tertiary referral centre.
03.04.01
Rupatadine fumarate
Allergic rhinitis
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD1
Rutosides
No Information Returned
Ruxolitinib
No Information Returned
 

For information about the icons and status values within this site, please refer to the keys below.

Icon/Links Key

NFD1
Non formulary
NFD2
Not assessed for formulary status. Apply to APC / DTC before use.
CD
Controlled drug. Prescribing and/or storage requirements may apply
R
Restrictions apply
SA
Safety Alert
U
Unlicensed - no UK marketing license in place
Un
Off-label use. Not licensed for this indication.
NHSE
Treatment commissioned by NHS England
CDF
CDF
ICB
Treatment commissioned by the ICB
BlueTeq
BlueTeq form to be completed
NICE
NICE

Traffic Light Status Key

Red
Specialist ONLY drugs - treatment initiated and continued by specialist clinicians
Amber
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care under a formal shared care agreement
Green
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing.
Black
Now referred to as "Non Formulary" but some BLACK drugs remain pending review. Not recommended for use in any health setting across Surrey and NW Sussex health economy.
Amber Star
Now referred to as "Blue" but some Amber Star drugs remain pending review. Prescribing initiated and stabliised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green (see narrative)
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing. Please refer to the narrative on the Drug Profile page where additional information may be conveyed as to the place in therapy or restrictions for use that have been locally agreed.
Non Formulary
Not recommended for use in any health setting across Surrey and NW Sussex health economy. (Formerly BLACK traffic light status)
See Below
Please add a description.
N/A
Please add a description.
Blue
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green - Black
Now referred to as "Do not initiate in new patients" but some GREEN/BLACK drugs remain pending review. These drugs are NOT for new initiations (BLACK, (now referred to as Non Formulary)) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required.
See narrative
See narrative - is applied in instances where there may be more than one traffic light status for a drug. This occurs when the traffic light status may differ between specific cohorts of patients e.g. those of childbearing potential and those who are not (in the case of sodium valproate)
Do not initiate in new patients
These drugs are NOT for new initiations (Non Formulary) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required. (Formerly GREEN/BLACK traffic light status)
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More